Cost implications of reactive versus prospective testing for dihydropyrimidine dehydrogenase deficiency in patients with colorectal cancer: A single-institution experience

Simple item page
dc.contributor.authorMurphy, Con
dc.contributor.authorByrne, Stephen
dc.contributor.authorAhmed, Gul
dc.contributor.authorKenny, Andrew
dc.contributor.authorGallagher, James
dc.contributor.authorHarvey, Harry
dc.contributor.authorO'Farrell, Eoin
dc.contributor.authorBird, Brian
dc.date.accessioned2019-10-02T04:36:50Z
dc.date.available2019-10-02T04:36:50Z
dc.date.issued2018-10-01
dc.description.abstractBackground:Severe toxicity is experienced by a substantial minority of patients receiving fluoropyrimidine-based chemotherapy, with approximately 20% of these severe toxicities attributable to polymorphisms in the DPYD gene. The DPYD codes for the enzyme dihydropyrimidine dehydrogenase (DPD) important in the metabolism of fluoropyrimidine-based chemotherapy. We questioned whether prospective DPYD mutation analysis in all patients commencing such therapy would prove more cost-effective than reactive testing of patients experiencing severe toxicity.Methods:All patients experiencing severe toxicity from fluoropyrimidine-based chemotherapy for colorectal cancer in an Irish private hospital over a 3-year period were tested for 4 DPYD polymorphisms previously associated with toxicity. The costs associated with an index admission for toxicity in DPD-deficient patients were examined. A cost analysis was undertaken comparing the anticipated cost of implementing screening for DPYD mutations versus current usual care. One-way sensitivity analysis was conducted on known input variables. An alternative scenario analysis from the perspective of the Irish health-care payer (responsible for public hospitals) was also performed.Results:Of 134 patients commencing first-line fluoropyrimidine chemotherapy over 3 years, 30 (23%) patients developed grade 3/4 toxicity. Of these, 17% revealed heterozygote DPYD mutations. The cost of hospitalization for the DPYD-mutated patients was ?232 061, while prospectively testing all 134 patients would have cost ?23 718. Prospective testing would result in cost savings across all scenarios.Conclusions:The cost of hospital admission for severe chemotherapy-related toxicity is significantly higher than the cost of prospective DPYD testing of each patient commencing fluoropyrimidine chemotherapy.en
dc.description.statusPeer revieweden
dc.description.versionPublished Versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.articleid1559325818803042en
dc.identifier.citationMurphy, C., Byrne, S., Ahmed, G., Kenny, A., Gallagher, J., Harvey, H., O’Farrell, E. and Bird, B., 2018. Cost implications of reactive versus prospective testing for dihydropyrimidine dehydrogenase deficiency in patients with colorectal cancer: a single-institution experience. Dose-Response, 16(4), (1559325818803042). DOI:10.1177/1559325818803042en
dc.identifier.doi10.1177/1559325818803042en
dc.identifier.eissn1559-3258
dc.identifier.endpage6en
dc.identifier.issued4en
dc.identifier.journaltitleDose-Responseen
dc.identifier.startpage1en
dc.identifier.urihttps://hdl.handle.net/10468/8659
dc.identifier.volume16en
dc.language.isoenen
dc.publisherSage Publications Ltden
dc.relation.urihttps://journals.sagepub.com/doi/10.1177/1559325818803042
dc.rights© The Author(s) 2018en
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/en
dc.subjectDPYDen
dc.subjectFluoropyrimidineen
dc.subjectColorectal canceren
dc.subjectCost-effectivenessen
dc.subjectPharmacogenomicsen
dc.titleCost implications of reactive versus prospective testing for dihydropyrimidine dehydrogenase deficiency in patients with colorectal cancer: A single-institution experienceen
dc.typeArticle (peer-reviewed)en
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
1559325818803042.pdf
Size:
221.47 KB
Format:
Adobe Portable Document Format
Description:
Published version
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medicine - Journal Articles
Biochemistry and Cell Biology - Journal Articles
Pharmacy - Journal Articles